Predicine
Precision diagnostics and medicine
Hybrid
Some members of the team work remotely, while others are co-located in one or more offices.
👥51-200
📍Hayward, California, United States
Predicine
About Predicine
Predicine is a global molecular insights company that is committed to advancing precision medicine in oncology and infectious diseases.
What Predicine is building
Predicine has developed a breakthrough cell-free DNA- and cell-free RNA-based liquid biopsy technology enabling minimally invasive molecular diagnosis for treatment selection, therapy monitoring, and minimal residual disease and early cancer detection.
Technologies used at Predicine
Back-end (6)
AWS
Java
Python
C++
C
RFunding rounds
Company type
For Profit
Predicine news and updates
Predicine, Inc. is developing cell-free DNA- and cell-free RNA-based liquid biopsy technology
Predicine is developing a proprietary cell-free DNA- and cell-free RNA-based liquid biopsy technology enabling minimally invasive molecular diagnosis for treatment selection, therapy monitoring, and minimal residual disease and early cancer detection.
Jan 1, 2022 | yahoo.comPredicine, Inc. is developing portfolio of liquid biopsy and tissue NGS
Predicine is developing a portfolio of liquid biopsy and tissue NGS assays for early cancer detection, treatment selection, therapy monitoring, minimal residual disease (MRD) monitoring and disease progression.
Jan 1, 2022 | biospace.comPredicine, Inc. launches PredicineCARE
Predicine, Inc., a global molecular insights company, has launched its CE-marked PredicineCARE™ for genomic profiling in blood and urine.
Jan 1, 2022 | yahoo.comPredicine, Inc. received financing of $13.5M in Series A round of financing on Apr 16th 18'.
Predicine announced today that it has closed a $13.5 million Series A round of financing.
Apr 16, 2018 | genomeweb.com